You're still missing the point.
1) As sales of Sprix increase, so does deficit. Sprix has zero managed care formulary coverage. Every prescripton filled actually costs the company money. As sales increase, so does the rate the corporate debt is repaid to the lender. Doubling the negative effect of the transaction.
2) Sprix was not and is not the short or long term backbone of Egalet as an organization. Sprix has a loss of exclusivity in the very near future. Guardian Technology is supposed to be the revenue engine to propel Egalet to profitability. Whether that can happen before the company is in serious financial trouble - the jury is still out.
3) Egalet has to pay for that copromotion. That payment can be structured in a variety of ways, but they are still PAYING. As a matter of opinion, I find it poor management of labor and financial resources to co-promote Sprix. Egalet converted their sales team from CSO to bring them on house. The Sprix sales force only has responsibility for 1 product. Sprix is their singular responsibility. Why cant that team get the job done? Why is there a need to waste sparse funds on a co-promotion? Why not co-promote behind Arymo ER, to put gas on the fire before competitors enter the market with better access and affordability? That would be the more logical decision.
Not a hater, a realist. And an intelligent one. Do you really believe that there is an entire marketplace of employees and investors who lost a LOT of money conspiring against the success of Egalet just to be "haters?" Come on. The fact that the word "haters" was used....is Egalet recruiting 8th graders now? Cheaper, I guess. Egalet loves cheap salespeople. And you get what you pay for.